Lion's Mane is the most commercially viable neurological compound in our database for the UK supplement market — it's legal, widely available, and has a growing clinical evidence base for cognitive decline. The mechanism (Erinacine A crossing the blood-brain barrier and directly stimulating NGF production) is elegant and well-characterised. The MCI trial (n=49) is the most clinically meaningful study — the effect in patients with early Alzheimer's is more compelling than the mixed results in healthy adults. Priority action: apply for Novel Food clearance on the mycelium extract form, then support an NIHR-funded Phase II RCT in MCI patients to build toward THR and eventual Full MA for cognitive decline indication.

Reishi carries the strongest immune evidence of any compound in this database. An 83% increase in NK cell cytotoxicity in a blinded RCT is a substantial pharmacological effect — comparable to pharmaceutical immunostimulants but without their side effect profile. The Cochrane review (highest level of evidence in medicine) endorses its role as a cancer adjuvant. Strategic priority: position Reishi as a cancer treatment support supplement with THR registration, then build toward a Phase II RCT as NHS oncology adjuvant. The GW Pharmaceuticals pathway (natural compound → NHS prescription) is the template.

Turkey Tail PSK has been a licensed pharmaceutical cancer adjuvant in Japan for 50+ years — this is not speculative, it is proven clinical medicine in another major market. A 9% absolute mortality reduction translates to NNT=11, meaning for every 11 cancer patients treated with PSK alongside standard care, one additional patient survives at 5 years. This is a clinically meaningful effect. The UK Novel Food restriction is a commercial obstacle, not a scientific one. Filing a FSA Novel Foods application now (18-36 month runway) positions BIOFORGE to commercialise this compound the moment authorization is granted.

Psilocybin is the most clinically significant compound in this entire database. A Phase 3 trial with 1,000+ patients achieving primary endpoint — published in the New England Journal of Medicine — is not preliminary science. It is pharmaceutical-grade evidence. The comparison to escitalopram (one of the world's most prescribed antidepressants) showing equivalence or superiority with a single dose vs 6 weeks of daily medication is a paradigm shift. BIOFORGE's role: monitor MHRA approval pathway for COMP360, build relationships with approved research centres (Imperial, KCL), and position for commercial access the moment Schedule 1 restrictions are modified.

Ashwagandha (specifically the KSM-66 standardised extract) is the most robustly evidenced adaptogen in our database. A 27.9% reduction in serum cortisol in a blinded RCT is a substantial hormonal effect. The drug interaction profile is clean, it's THR-eligible in the UK, and consumer market penetration is already high — meaning brand recognition supports commercial launch. BIOFORGE strategy: THR registration using the 3,000-year traditional use history, position alongside the emerging clinical data, and target the burnout/stress epidemic market that is £B+ in the UK alone.

Artemisinin is the most important proof-of-concept in natural medicine history — a compound extracted from a plant (Artemisia annua, used in Chinese medicine for 2,000 years) that became the world's primary anti-malarial treatment, earned its discoverer a Nobel Prize, and saves millions of lives annually. This is the template for everything BIOFORGE is building: traditional knowledge → rigorous science → full pharmaceutical approval → global impact. Every compound in this database is following the same pathway.

Acerola is the immediate commercial opportunity. Nine approved health claims means we can make specific, legal statements about immune function, collagen synthesis, fatigue reduction, and cognitive function — right now, without any additional regulatory hurdles. The bioavailability advantage over synthetic Vitamin C (SVCT1 transporter specificity for natural L-ascorbic acid) is a genuine differentiator for premium product positioning.

The 2012 RCT showing Amla producing LDL reduction equivalent to a statin is one of the most commercially powerful data points in this entire database. Statins are the world's most prescribed drug class. If a fruit extract can match their lipid-lowering effect without their side effect profile (myopathy, CoQ10 depletion, liver stress), that is a legitimate medical story. Priority: replicate in a larger UK-based RCT with NIHR funding, then file THR application and begin investor conversations.

Elderberry has multiple RCTs (Zakay-Rones protocols) showing reduction in flu duration and severity. THR registration is straightforward given the centuries of European use. A premium elderberry extract standardised for anthocyanin content is a first-to-market THR product opportunity — combine with AeroWell for a respiratory wellness product bundle.

Magnesium deficiency affects 60-80% of the UK population. The L-Threonate form specifically crosses the blood-brain barrier (unlike glycinate or citrate forms) — the Neuron paper is a top-tier publication proving this mechanism. Two distinct product lines: Magnesium Glycinate for sleep/anxiety (established market), Magnesium L-Threonate for cognitive enhancement (premium, emerging market). Stack with Lion's Mane for a comprehensive cognitive support formula.

Q-SYMBIO is the strongest nutraceutical cardiology trial ever conducted. Halving cardiovascular mortality in heart failure patients with a natural compound is a landmark result. Additionally: statins (taken by millions in the UK) deplete CoQ10 as a side effect — this is the mechanism behind statin-associated myopathy. A CoQ10 product positioned specifically for statin users is a clearly addressable market with a direct mechanistic rationale.

Papakostas 2012 showed active methylfolate doubles SSRI response rate in treatment-resistant depression. The mechanism (25% of the population have MTHFR gene variants that impair folic acid conversion, meaning they need the pre-activated 5-MTHF form directly) is well-characterised. This makes 5-MTHF a precision medicine opportunity — potentially the first genetically-targetable natural medicine product in our pipeline.

Berberine matching metformin in a head-to-head RCT is the most commercially powerful individual study finding in this database. Metformin is prescribed to 200+ million people globally. Berberine achieves equivalent HbA1c reduction via AMPK activation (same pathway) with additional cardiovascular benefits (LDL −25%, TG −35%) and without metformin's GI side effects or B12 depletion. Target market: 4.9 million UK diabetics + pre-diabetics. Regulatory route: food supplement (immediate) → THR for metabolic support claim → Full MA for T2DM indication (long-term).

NAC is the only compound in this database that is simultaneously a hospital emergency treatment (acetaminophen overdose), a clinical respiratory drug (nebulized in COPD), and a consumer supplement. This regulatory duality is commercially interesting — it exists in both the pharmaceutical and supplement worlds. The AeroWell device clinical variant (NAC nebulization pods) leverages this: a consumer device with a medical-grade clinical upgrade pathway.